Abstract
Approximately 50% of patients with localized soft tissue sarcomas will develop recurrent disease after complete surgical resection, requiring alternative means of treatment. Conventional chemotherapy comprising of doxorubicin and ifosfamide has shown benefit in advanced disease, however, there remains a clear need for more effective, less toxic, therapies for the treatment of this heterogeneous group of mesenchymal malignancies. Recently, greater emphasis has been placed on the underlying biology of individual sarcoma subtypes, with the development and evaluation of novel therapies both in common and in rare subtypes. In addition, there is a greater specificity in the selection of chemotherapy agents based on activity in individual histological subtypes. Despite these advances the management of sarcoma, and in particular of rare subtypes, remains a major challenge. Some histological subtypes are resistant to conventional chemotherapy and patients with these diseases should be offered participation in early phase clinical trials of novel drugs.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 211-223 |
| Number of pages | 13 |
| Journal | Expert Review of Anticancer Therapy |
| Volume | 13 |
| Issue number | 2 |
| DOIs | |
| State | Published - Feb 2013 |
| Externally published | Yes |
Fingerprint
Keywords
- angiogenesis
- gemcitabine/docetaxel
- pazopanib
- rare histological subtype
- sarcoma
- systemic therapy
- trabectedin
ASJC Scopus subject areas
- Pharmacology (medical)
- Oncology
Cite this
The evolution of systemic therapy in sarcoma. / Constantinidou, Anastasia; Pollack, Seth; Loggers, Elizabeth; Rodler, Eve; Jones, Robin L.
In: Expert Review of Anticancer Therapy, Vol. 13, No. 2, 02.2013, p. 211-223.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The evolution of systemic therapy in sarcoma
AU - Constantinidou, Anastasia
AU - Pollack, Seth
AU - Loggers, Elizabeth
AU - Rodler, Eve
AU - Jones, Robin L.
PY - 2013/2
Y1 - 2013/2
N2 - Approximately 50% of patients with localized soft tissue sarcomas will develop recurrent disease after complete surgical resection, requiring alternative means of treatment. Conventional chemotherapy comprising of doxorubicin and ifosfamide has shown benefit in advanced disease, however, there remains a clear need for more effective, less toxic, therapies for the treatment of this heterogeneous group of mesenchymal malignancies. Recently, greater emphasis has been placed on the underlying biology of individual sarcoma subtypes, with the development and evaluation of novel therapies both in common and in rare subtypes. In addition, there is a greater specificity in the selection of chemotherapy agents based on activity in individual histological subtypes. Despite these advances the management of sarcoma, and in particular of rare subtypes, remains a major challenge. Some histological subtypes are resistant to conventional chemotherapy and patients with these diseases should be offered participation in early phase clinical trials of novel drugs.
AB - Approximately 50% of patients with localized soft tissue sarcomas will develop recurrent disease after complete surgical resection, requiring alternative means of treatment. Conventional chemotherapy comprising of doxorubicin and ifosfamide has shown benefit in advanced disease, however, there remains a clear need for more effective, less toxic, therapies for the treatment of this heterogeneous group of mesenchymal malignancies. Recently, greater emphasis has been placed on the underlying biology of individual sarcoma subtypes, with the development and evaluation of novel therapies both in common and in rare subtypes. In addition, there is a greater specificity in the selection of chemotherapy agents based on activity in individual histological subtypes. Despite these advances the management of sarcoma, and in particular of rare subtypes, remains a major challenge. Some histological subtypes are resistant to conventional chemotherapy and patients with these diseases should be offered participation in early phase clinical trials of novel drugs.
KW - angiogenesis
KW - gemcitabine/docetaxel
KW - pazopanib
KW - rare histological subtype
KW - sarcoma
KW - systemic therapy
KW - trabectedin
UR - http://www.scopus.com/inward/record.url?scp=84873926745&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84873926745&partnerID=8YFLogxK
U2 - 10.1586/era.12.161
DO - 10.1586/era.12.161
M3 - Article
C2 - 23406562
AN - SCOPUS:84873926745
VL - 13
SP - 211
EP - 223
JO - Expert Review of Anticancer Therapy
JF - Expert Review of Anticancer Therapy
SN - 1473-7140
IS - 2
ER -